(CE) Celanese - Ratings and Ratios
Acetic Acid, Nylon, Resins, Polymers, Elastomers
CE EPS (Earnings per Share)
CE Revenue
Description: CE Celanese
Celanese Corporation is a global chemical and specialty materials company that produces a wide range of engineered polymers and acetyl products for various industries, including automotive, medical, industrial, and consumer goods. The companys diverse product portfolio is sold under multiple brands, catering to original equipment manufacturers and suppliers through direct sales and distribution channels.
From a business perspective, Celanese operates through two main segments: Engineered Materials and Acetyl Chain. The Engineered Materials segment focuses on high-performance polymers for demanding applications, while the Acetyl Chain segment produces a range of acetyl products used in various industrial and consumer applications. Key performance indicators (KPIs) to watch for Celanese include revenue growth, segmental profitability, and return on invested capital (ROIC). Given the companys exposure to diverse end-markets, tracking industry trends and demand drivers will be crucial in assessing its future prospects.
To evaluate Celaneses financial health, key metrics such as debt-to-equity ratio, interest coverage, and cash flow conversion should be monitored. The companys current valuation multiples, such as the forward P/E ratio of 11.86, can be compared to industry peers to gauge relative attractiveness. Additionally, return on equity (ROE) has been negative, indicating potential challenges in generating profits for shareholders. However, a more detailed analysis of the companys financial statements and industry trends would be necessary to form a comprehensive view.
From a growth perspective, Celaneses ability to innovate and expand its product offerings in high-growth areas, such as electric vehicles and renewable energy, will be critical. The companys research and development (R&D) efforts, as well as its strategic acquisitions and partnerships, should be closely followed to assess its potential for long-term growth. Key growth KPIs to monitor include revenue CAGR, EBITDA margin expansion, and the success of new product launches.
CE Stock Overview
| Market Cap in USD | 5,094m |
| Sub-Industry | Specialty Chemicals |
| IPO / Inception | 2005-01-21 |
CE Stock Ratings
| Growth Rating | -75.3% |
| Fundamental | 42.1% |
| Dividend Rating | 38.9% |
| Return 12m vs S&P 500 | -69.5% |
| Analyst Rating | 3.44 of 5 |
CE Dividends
| Dividend Yield 12m | 1.53% |
| Yield on Cost 5y | 0.79% |
| Annual Growth 5y | 2.46% |
| Payout Consistency | 99.0% |
| Payout Ratio | 13.4% |
CE Growth Ratios
| Growth Correlation 3m | -76.9% |
| Growth Correlation 12m | -81.5% |
| Growth Correlation 5y | -43% |
| CAGR 5y | -21.40% |
| CAGR/Max DD 3y | -0.27 |
| CAGR/Mean DD 3y | -1.59 |
| Sharpe Ratio 12m | -1.33 |
| Alpha | 0.00 |
| Beta | 0.990 |
| Volatility | 53.22% |
| Current Volume | 2195.7k |
| Average Volume 20d | 1860.4k |
| Stop Loss | 42.6 (-5.6%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-1.62b TTM) > 0 and > 6% of Revenue (6% = 596.3m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.69pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.26% (prev 12.11%; Δ 17.15pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.02b > Net Income -1.62b (YES >=105%, WARN >=100%) |
| Net Debt (12.14b) to EBITDA (247.0m) ratio: 49.15 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.05 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (109.7m) change vs 12m ago 0.17% (target <= -2.0% for YES) |
| Gross Margin 21.85% (prev 23.51%; Δ -1.65pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 40.14% (prev 40.89%; Δ -0.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.74 (EBITDA TTM 247.0m / Interest Expense TTM 711.0m) >= 6 (WARN >= 3) |
Altman Z'' 2.81
| (A) 0.12 = (Total Current Assets 5.67b - Total Current Liabilities 2.77b) / Total Assets 23.71b |
| (B) 0.47 = Retained Earnings (Balance) 11.24b / Total Assets 23.71b |
| (C) -0.02 = EBIT TTM -525.0m / Avg Total Assets 24.76b |
| (D) 0.57 = Book Value of Equity 10.34b / Total Liabilities 18.01b |
| Total Rating: 2.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.09
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield 3.73% = 1.87 |
| 3. FCF Margin 6.36% = 1.59 |
| 4. Debt/Equity 2.47 = 0.05 |
| 5. Debt/Ebitda 52.71 = -2.50 |
| 6. ROIC - WACC data missing |
| 7. RoE -28.28% = -2.50 |
| 8. Rev. Trend -7.52% = -0.56 |
| 9. EPS Trend -56.97% = -2.85 |
What is the price of CE shares?
Over the past week, the price has changed by +2.01%, over one month by +4.64%, over three months by -17.16% and over the past year by -63.87%.
Is Celanese a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CE is around 33.66 USD . This means that CE is currently overvalued and has a potential downside of -25.38%.
Is CE a buy, sell or hold?
- Strong Buy: 5
- Buy: 0
- Hold: 12
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the CE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54.7 | 21.2% |
| Analysts Target Price | 54.7 | 21.2% |
| ValueRay Target Price | 37.9 | -15.9% |
Last update: 2025-09-09 04:33
CE Fundamental Data Overview
CCE Cash And Equivalents = 1.17b USD (last quarter)
P/E Forward = 8.5251
P/S = 0.5125
P/B = 1.0114
P/EG = 4.4198
Beta = 1.108
Revenue TTM = 9.94b USD
EBIT TTM = -525.0m USD
EBITDA TTM = 247.0m USD
Long Term Debt = 12.69b USD (from longTermDebt, last quarter)
Short Term Debt = 330.0m USD (from shortTermDebt, last quarter)
Debt = 13.02b USD (Calculated: Short Term 330.0m + Long Term 12.69b)
Net Debt = 12.14b USD (from netDebt column, last quarter)
Enterprise Value = 16.94b USD (5.09b + Debt 13.02b - CCE 1.17b)
Interest Coverage Ratio = -0.74 (Ebit TTM -525.0m / Interest Expense TTM 711.0m)
FCF Yield = 3.73% (FCF TTM 632.0m / Enterprise Value 16.94b)
FCF Margin = 6.36% (FCF TTM 632.0m / Revenue TTM 9.94b)
Net Margin = -16.30% (Net Income TTM -1.62b / Revenue TTM 9.94b)
Gross Margin = 21.85% ((Revenue TTM 9.94b - Cost of Revenue TTM 7.77b) / Revenue TTM)
Tobins Q-Ratio = 1.64 (Enterprise Value 16.94b / Book Value Of Equity 10.34b)
Interest Expense / Debt = 1.36% (Interest Expense 177.0m / Debt 13.02b)
Taxrate = -57.04% (set to none) (-77.0m / 135.0m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.05 (Total Current Assets 5.67b / Total Current Liabilities 2.77b)
Debt / Equity = 2.47 (Debt 13.02b / last Quarter total Stockholder Equity 5.28b)
Debt / EBITDA = 52.71 (Net Debt 12.14b / EBITDA 247.0m)
Debt / FCF = 20.60 (Debt 13.02b / FCF TTM 632.0m)
Total Stockholder Equity = 5.73b (last 4 quarters mean)
RoA = -6.83% (Net Income -1.62b, Total Assets 23.71b )
RoE = -28.28% (Net Income TTM -1.62b / Total Stockholder Equity 5.73b)
RoCE = -2.85% (Ebit -525.0m / (Equity 5.73b + L.T.Debt 12.69b))
RoIC = unknown (NOPAT none, Invested Capital 18.54b, Ebit -525.0m)
WACC = unknown (E(5.09b)/V(18.11b) * Re(9.66%)) + (D(13.02b)/V(18.11b) * Rd(1.36%) * (1-Tc(none)))
Shares Correlation 3-Years: 62.60 | Cagr: 0.06%
Discount Rate = 9.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.26% ; FCFE base≈829.2m ; Y1≈696.4m ; Y5≈521.0m
Fair Price DCF = 67.00 (DCF Value 7.34b / Shares Outstanding 109.5m; 5y FCF grow -19.38% → 3.0% )
EPS Correlation: -56.97 | EPS CAGR: -30.65% | SUE: 0.15 | # QB: 0
Revenue Correlation: -7.52 | Revenue CAGR: 3.54% | SUE: 0.56 | # QB: 0
Additional Sources for CE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle